Welcure Drugs Restates FY26 Results Following Auditor Warnings

Total Income for FY26 stands at Rs 390.99 crore; Net Loss reported at Rs 5.67 crore.

Reader Takeaway: Restated numbers confirm a shift to loss, while auditors flag critical missing evidence for inventory and supplier advances.

What just happened

Welcure Drugs & Pharmaceuticals Ltd has filed revised audited financial results for the quarter and year ended March 31, 2026. This submission replaces a previous filing from May 2026, citing the correction of inadvertent errors. The company reported a total income of Rs 390.99 crore for the full year, against total expenses of Rs 396.66 crore.

Why this matters

The restatement comes alongside a troubling report from the statutory auditor. While the opinion is technically 'unmodified,' the auditor raised several red flags regarding the company’s internal controls and asset verification. Specifically, the auditor stated they could not verify the existence or valuation of Rs 143.52 crore in inventory, as the company lacks warehousing records and standard inward reports. Furthermore, Rs 151.26 crore in supplier advances remain unconfirmed.

Risks to watch

Investors should monitor the severe gaps in documentation identified by the auditor, including missing E-Way bills and delivery challans for sales. Additionally, the company’s failure to provide MSME creditor bifurcation is a regulatory compliance risk under the MSMED Act. The lack of external confirmation for significant trade receivables and payables poses a material risk to the reliability of the company’s financial health assessment.

What to track next

Shareholders should look for management’s formal response to these auditor concerns, specifically regarding the existence of inventory and the process for verifying trade payables. Further clarification on how the company plans to address the documentation deficiencies and statutory compliance failures is essential for retail investors assessing the company's governance standards.